Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jaguar Health, Inc.JAGX · Entity 8387 | Director | December 11, 2025 | December 15, 2025 |
| Lineage Cell Therapeutics, Inc.LCTX · Entity 6045 | Director | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jaguar Health, Inc.
Report date December 11, 2025 · Filed December 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,916 |
Reported balance
After 2025-12-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-11 · Grant · Acquired 5,870 · Balance 5,916 F1: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice. F4: On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2024 Reverse Stock Split"). Upon effectiveness of the 2024 Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock. F5: On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2025 Reverse Stock Split"). Upon effectiveness of the 2025 Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.44 · Expires 2035-12-11 | Direct | 5,870 |
Reported balance
After 2025-12-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-11 · Grant · Acquired 5,870 · Balance 5,870 F1: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. F6: The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the reporting person continues to serve on the board of directors of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the issuer's 2014 Stock Incentive Plan.
F2: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.
F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice.
F4: On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2024 Reverse Stock Split"). Upon effectiveness of the 2024 Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock.
F5: On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2025 Reverse Stock Split"). Upon effectiveness of the 2025 Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.
F6: The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the reporting person continues to serve on the board of directors of the issuer.
Lineage Cell Therapeutics, Inc.
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2036-07-01 | Direct | 125,000 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 125,000 · Balance 125,000 F1: Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 2, 2026 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001193125-26-294873 · ownership.xml · derivative · entry 1 Jayasuriya Anula · CIK 0001822933 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2036-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 22:50 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 5,870 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001193125-25-319508 · ownership.xml · derivative · entry 2 Jayasuriya Anula · CIK 0001822933 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,870 Underlying: Common Stock · 5,870 shares Expires 2035-12-11 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. F6 · derivative.exercise_date: The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the reporting person continues to serve on the board of directors of the issuer. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 22:50 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantCommon Stock | 5,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-319508 · ownership.xml · nonDerivative · entry 1 Jayasuriya Anula · CIK 0001822933 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,916 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. F3 · date: Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice. F4 · balance_after: On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2024 Reverse Stock Split"). Upon effectiveness of the 2024 Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock. F5 · balance_after: On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2025 Reverse Stock Split"). Upon effectiveness of the 2025 Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0000950170-25-093469 · ownership.xml · derivative · entry 1 Jayasuriya Anula · CIK 0001822933 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2035-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on the earlier of July 1, 2026 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer. Read SEC document |
| October 08, 2024 Filed Oct 11, 2024 01:53 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock option (right to buy) · Derivative | 21,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000950170-24-114183 · ownership.xml · derivative · entry 1 Jayasuriya Anula · CIK 0001822933 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2034-10-08 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The option grant was approved by the issuer's board of directors on October 8, 2024. F3 · derivative.exercise_date: The options will vest 100% on the first anniversary of the grant date, so long as the reporting person continues to serve on the board of directors of the issuer. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000950170-24-081604 · ownership.xml · derivative · entry 1 Jayasuriya Anula · CIK 0001822933 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2034-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on July 1, 2025, subject to the reporting person's continuous service with the issuer. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 00:08 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | PurchaseCommon Shares, no par value | 10,000 | $1.09 | $10,900.00 |
DisclosureSEC source: 0001493152-24-000154 · ownership.xml · nonDerivative · entry 1 Jayasuriya Anula · CIK 0001822933 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.08 to not more than $1.09. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range. F2 · balance_after: Does not include common shares that may be acquired upon the exercise of stock options outstanding as of the date of this report. Read SEC document |
| August 14, 2023 Filed Aug 14, 2023 20:55 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantCommon Stock | 68,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-091463 · tm2322677-3_4seq1.xml · nonDerivative · entry 2 Jayasuriya Anula · CIK 0001822933 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,286 Read SEC document |
| July 01, 2023 Filed Jul 3, 2023 21:45 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001493152-23-023345 · ownership.xml · derivative · entry 1 Jayasuriya Anula · CIK 0001822933 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2033-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer. Read SEC document |
| July 01, 2023 Filed Aug 14, 2023 20:55 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantRestricted stock units · Derivative | 1,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-091463 · tm2322677-3_4seq1.xml · derivative · entry 3 Jayasuriya Anula · CIK 0001822933 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,718 shares Expires not disclosed F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan (the "Plan"). F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The RSUs vested in full on July 1, 2023, the first anniversary of the service start date. Vested shares were delivered to the reporting person on the vesting date provided in the grant notice, subject to the reporting person's continuous services through such vesting date. F3 · derivative.expiration_date: The RSUs vested in full on July 1, 2023, the first anniversary of the service start date. Vested shares were delivered to the reporting person on the vesting date provided in the grant notice, subject to the reporting person's continuous services through such vesting date. Read SEC document |
| July 01, 2023 Filed Aug 14, 2023 20:55 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantCommon Stock | 1,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-091463 · tm2322677-3_4seq1.xml · nonDerivative · entry 1 Jayasuriya Anula · CIK 0001822933 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,718 Read SEC document |
| April 06, 2023 Filed Apr 6, 2023 20:26 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantRestricted stock units · Derivative | 1,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-042746 · tm2311973-1_4seq1.xml · derivative · entry 1 Jayasuriya Anula · CIK 0001822933 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,718 Underlying: Common Stock · 1,718 shares Expires not disclosed F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan (the "Plan"). F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock. F3 · date: The RSU grant, effective April 6, 2023, was approved by the issuer's board of directors on June 30, 2022, subject to the issuer having sufficient authorized shares of common stock under the Plan on or before June 30, 2023. Following the issuer's filing of a registration statement on Form S-8 on April 6, 2023 to reflect the automatic increase in the number of shares of common stock authorized for issuance under the 2014 Plan in an amount equal to 5% of the total number of shares outstanding on December 31st of the preceding calendar year pursuant to the terms of the Plan, the Company had sufficient authorized shares of common stock under the Plan for the RSU grant and the RSU grant became effective as of such date. F4 · shares: The issuer's board of directors originally approved the grant of 128,851 RSUs on June 30, 2022, subject to the conditions described in footnote 3 above. On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. As a result, the 128,851 RSUs originally approved by the Board were adjusted to 1,718 RSUs to reflect the Reverse Stock Split. F5 · derivative.exercise_date: The RSUs vest in full on July 1, 2023, the first anniversary of the service start date. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice, subject to the reporting person's continuous services through such vesting date. F5 · derivative.expiration_date: The RSUs vest in full on July 1, 2023, the first anniversary of the service start date. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice, subject to the reporting person's continuous services through such vesting date. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:15 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001493152-22-018683 · ownership.xml · derivative · entry 1 Jayasuriya Anula · CIK 0001822933 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2032-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on July 1, 2023, subject to the reporting person's continuous service with the issuer. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 22:17 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001493152-21-015880 · ownership.xml · derivative · entry 1 Jayasuriya Anula · CIK 0001822933 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on July 1, 2022, subject to the reporting person's continuous service with the issuer. Read SEC document |
| May 04, 2021 Filed May 6, 2021 21:48 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001493152-21-010668 · ownership.xml · derivative · entry 1 Jayasuriya Anula · CIK 0001822933 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Shares · 90,000 shares Expires 2031-05-03 F1 · derivative.exercise_date: This option vests in 36 monthly installments beginning on the one-month anniversary of the date of grant, subject to the reporting person's continuous service on the board of directors of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.